NO314783B1 - Farmasoytiske formuleringer inneholdende darifenacin - Google Patents

Farmasoytiske formuleringer inneholdende darifenacin Download PDF

Info

Publication number
NO314783B1
NO314783B1 NO19981073A NO981073A NO314783B1 NO 314783 B1 NO314783 B1 NO 314783B1 NO 19981073 A NO19981073 A NO 19981073A NO 981073 A NO981073 A NO 981073A NO 314783 B1 NO314783 B1 NO 314783B1
Authority
NO
Norway
Prior art keywords
darifenacin
pharmaceutically acceptable
released
dosage form
acceptable salt
Prior art date
Application number
NO19981073A
Other languages
English (en)
Norwegian (no)
Other versions
NO981073D0 (no
NO981073L (no
Inventor
Thomas Francis Dolan
Michael John Humphrey
Donald John Nichols
Original Assignee
Novartis International Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10780813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO314783(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis International Pharmaceutical Ltd filed Critical Novartis International Pharmaceutical Ltd
Publication of NO981073D0 publication Critical patent/NO981073D0/no
Publication of NO981073L publication Critical patent/NO981073L/no
Publication of NO314783B1 publication Critical patent/NO314783B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19981073A 1995-09-15 1998-03-11 Farmasoytiske formuleringer inneholdende darifenacin NO314783B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9518953.6A GB9518953D0 (en) 1995-09-15 1995-09-15 Pharmaceutical formulations
PCT/EP1996/003719 WO1997009980A1 (en) 1995-09-15 1996-08-21 Pharmaceutical formulations containing darifenacin

Publications (3)

Publication Number Publication Date
NO981073D0 NO981073D0 (no) 1998-03-11
NO981073L NO981073L (no) 1998-03-11
NO314783B1 true NO314783B1 (no) 2003-05-26

Family

ID=10780813

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19981073A NO314783B1 (no) 1995-09-15 1998-03-11 Farmasoytiske formuleringer inneholdende darifenacin
NO2005009C NO2005009I2 (no) 1995-09-15 2005-04-08 Emselex-darifenacin. Iupac-navn: (S)-2-ä1-Ä2-(2,3 -dihydrobenzofuran-5-yl)etylÜ-3-pyrrolidinylü-2,2-difenylacetamid

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2005009C NO2005009I2 (no) 1995-09-15 2005-04-08 Emselex-darifenacin. Iupac-navn: (S)-2-ä1-Ä2-(2,3 -dihydrobenzofuran-5-yl)etylÜ-3-pyrrolidinylü-2,2-difenylacetamid

Country Status (32)

Country Link
US (1) US6106864A (cs)
EP (2) EP0850059B1 (cs)
JP (1) JP3403203B2 (cs)
KR (1) KR100348585B1 (cs)
CN (1) CN1303998C (cs)
AR (1) AR005231A1 (cs)
AT (2) ATE233090T1 (cs)
BR (2) BR9610153A (cs)
CA (1) CA2230314C (cs)
CO (1) CO4750822A1 (cs)
CY (3) CY2468B1 (cs)
CZ (1) CZ294024B6 (cs)
DE (4) DE122005000024I1 (cs)
DK (2) DK1245231T3 (cs)
EG (1) EG23826A (cs)
ES (2) ES2224002T3 (cs)
FR (1) FR05C0019I2 (cs)
GB (1) GB9518953D0 (cs)
HU (2) HU227397B1 (cs)
IL (1) IL122746A (cs)
LU (1) LU91163I2 (cs)
MY (1) MY125662A (cs)
NL (1) NL300190I2 (cs)
NO (2) NO314783B1 (cs)
NZ (1) NZ316924A (cs)
PL (1) PL185604B1 (cs)
PT (1) PT1245231E (cs)
RU (1) RU2163803C2 (cs)
TR (1) TR199800461T1 (cs)
TW (1) TW442300B (cs)
WO (1) WO1997009980A1 (cs)
ZA (1) ZA967745B (cs)

Families Citing this family (312)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502302A (ja) * 1996-09-19 2001-02-20 アメリカン・ホーム・プロダクツ・コーポレイション 尿失禁を治療する方法
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US7858119B1 (en) * 2000-05-09 2010-12-28 Amina Odidi Extended release pharmaceuticals
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
GB0129962D0 (en) * 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−２−δリガンド
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040235857A1 (en) * 2003-02-11 2004-11-25 Pfizer Inc Crystalline therapeutic agent
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040186046A1 (en) * 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
ATE433978T1 (de) 2003-04-29 2009-07-15 Pfizer Ltd 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
US7268147B2 (en) * 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20050043300A1 (en) * 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives
OA13248A (en) * 2003-09-03 2007-01-31 Pfizer Benzimidazolone coumpounds having 5-HT4 receptor agonistic activity.
JP2007505097A (ja) 2003-09-12 2007-03-08 ファイザー・インク アルファ−２−デルタリガンドとセロトニン／ノルアドレナリン再取込み阻害薬を含む組合せ
MXPA06003749A (es) * 2003-10-03 2006-06-14 Pfizer Derivados de tropano.
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
GB0402491D0 (en) * 2004-02-04 2004-03-10 Pfizer Ltd Medicaments
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7629358B2 (en) * 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
WO2005090313A1 (en) * 2004-03-18 2005-09-29 Pfizer Limited N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
US7538141B2 (en) * 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
EP1730103B1 (en) * 2004-03-23 2010-05-26 Pfizer Limited Formamide derivatives useful as adrenoceptor
US20050215542A1 (en) * 2004-03-23 2005-09-29 Pfizer Inc Compounds for the treatment of diseases
WO2005097799A1 (en) * 2004-04-07 2005-10-20 Pfizer Limited Pyrazolo`4,3-d! pyrimidines
EA200801607A1 (ru) * 2004-06-15 2008-10-30 Пфайзер Инк. Производные бензимидазолонкарбоновой кислоты
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
SI1778686T1 (sl) * 2004-08-12 2009-02-28 Pfizer Derivati triazolopiridinilsulfanila kot inhibitorji P38 MAP kinaze
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006021884A2 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
EA011725B1 (ru) * 2004-08-26 2009-04-28 Пфайзер Инк. Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
ES2318556T3 (es) * 2004-11-02 2009-05-01 Pfizer, Inc. Derivados de sulfonil bencimidazol.
US20060111416A1 (en) * 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
BRPI0608436A2 (pt) 2005-03-17 2009-12-29 Pfizer derivados de n-(n-sulfonilaminometil) ciclopropanocarboxamida utilizáveis para o tratamento de dor
US20110152326A1 (en) * 2005-03-28 2011-06-23 Takeshi Hanazawa Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists
US20070149464A1 (en) * 2005-06-15 2007-06-28 Pfizer Inc. Combination
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
US7645786B2 (en) * 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
BRPI0611798A2 (pt) * 2005-06-15 2009-01-13 Pfizer Ltd compostos de arilpirazàis substituÍdos, sua composiÇço farmacÊutica e uso
US20080269233A1 (en) * 2005-08-04 2008-10-30 Mark David Andrews Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
JP2009504628A (ja) * 2005-08-10 2009-02-05 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
ATE506059T1 (de) 2005-09-02 2011-05-15 Theravida Inc Therapie zur behandlung der überaktiven blase
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
EP2007360B1 (en) 2006-04-03 2014-11-26 Isa Odidi Controlled release delivery device comprising an organosol coat
RS20080525A (sr) 2006-05-09 2009-09-08 Pfizer Products Inc., Derivati cikloalkilamino kiseline i njihove farmaceutske kompozicije
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2008017932A2 (en) * 2006-08-09 2008-02-14 Pfizer Products Inc. Heterocycles useful as inhibitors of carbonic anhydrase
WO2008031221A1 (en) * 2006-09-12 2008-03-20 Cephalin Pharmaceuticals Inc. Isovaline for treatment of pain
RU2412188C2 (ru) * 2006-09-21 2011-02-20 Раквалиа Фарма Инк. Производные бензимидазола в качестве селективных ингибиторов кислотной помпы
WO2008050199A2 (en) 2006-10-23 2008-05-02 Pfizer Japan Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
RU2322998C1 (ru) * 2006-11-16 2008-04-27 Общество с ограниченной ответственностью "Березовый мир" Носитель лекарственных и диагностических средств
ATE518872T1 (de) * 2007-02-02 2011-08-15 Pfizer Prod Inc Trizyklische verbindungen und deren verwendung als glucocorticoidrezeptormodulatoren
CA2687944A1 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
CN101084891A (zh) * 2007-06-29 2007-12-12 北京本草天源药物研究院 一种用于口服的达非那新或其药用盐的药物制剂
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US8323695B2 (en) 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
US20110092564A1 (en) * 2008-02-26 2011-04-21 Ernest Puil Cyclic amino acids for the treatment of pain
WO2009140078A1 (en) * 2008-05-16 2009-11-19 The Procter & Gamble Company Treatment of lower urinary tract dysfunction with cb2-receptor-selective agonists
EP2286810A4 (en) * 2008-05-16 2011-07-20 Axis Inc PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FIBROMYALGIA
JP5553452B2 (ja) * 2008-05-30 2014-07-16 ユセベ ファルマ ソシエテ アノニム ブリバラセタムを含む医薬組成物
ES2378513T3 (es) * 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
EP2163253B1 (en) 2008-09-15 2013-07-17 ULLRICH, Oliver Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
RU2528406C2 (ru) 2008-11-21 2014-09-20 Раквалиа Фарма Инк. Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
UA105911C2 (uk) 2009-01-12 2014-07-10 Пфайзер Лімітед Сульфонамідні похідні
EP2406281B1 (en) 2009-03-12 2016-02-17 Haase Investments UG Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
EP2236516A1 (en) 2009-03-31 2010-10-06 Charité-Universitätsmedizin Berlin (Charité) Polypeptides and use thereof for treatment of traumatic or degenerative neuronal injury
CN102448978A (zh) 2009-05-29 2012-05-09 辉瑞有限公司 新颖的糖皮质激素受体激动剂
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
US8617763B2 (en) * 2009-08-12 2013-12-31 Bloom Energy Corporation Internal reforming anode for solid oxide fuel cells
US20130045948A1 (en) 2009-12-11 2013-02-21 E I Du Pont De Nemours And Company Azocyclic inhibitors of fatty acid amide hydrolase
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
SI2516434T1 (sl) 2009-12-23 2015-10-30 Takeda Pharmaceutical Company Limited Zliti heteroaromatski pirolidinoni kot inhibitorji SYK
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
WO2011161504A1 (en) 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
ES2532356T3 (es) 2010-07-09 2015-03-26 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
ES2526675T3 (es) 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
JP2013531030A (ja) 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
EP2593428B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
ES2526541T3 (es) 2010-07-12 2015-01-13 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
EP2593432B1 (en) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
RU2564445C2 (ru) 2010-11-15 2015-10-10 ВииВ Хелткер ЮКей Лимитед Ингибиторы репликации вич
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
TW201242971A (en) 2011-02-25 2012-11-01 Takeda Pharmaceutical N-substituted oxazinopteridines and oxazinopteridinones
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
CA2832291C (en) 2011-04-05 2015-12-01 Pfizer Limited Pyrrolo[2,3-d)pyrimidine tropomyosin-related kinase inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
US20120289562A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
EP3167885A1 (en) 2011-05-10 2017-05-17 TheraVida, Inc. Combinations of solifenacin and pilocarpine for the treatment of overactive bladder
CA2836372C (en) 2011-05-18 2020-09-22 Raqualia Pharma Inc. Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
HK1198133A1 (en) 2011-08-02 2015-03-13 辉瑞公司 Crizotinib for use in the treatment of cancer
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
CN104271128A (zh) 2011-10-19 2015-01-07 佐蒂斯有限责任公司 氨基乙腈衍生物针对体内寄生虫的用途
JP5363636B2 (ja) 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
PE20141682A1 (es) 2011-10-26 2014-11-14 Pfizer Ltd Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
IN2014DN03063A (cs) 2011-10-28 2015-05-15 Inhibitaxin Ltd
ES2593533T3 (es) 2011-12-15 2016-12-09 Pfizer Limited Derivados de sulfonamida
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
CN102579379B (zh) * 2011-12-29 2016-08-10 北京科信必成医药科技发展有限公司 一种药物缓释制剂及其制备方法
CN102600096B (zh) * 2011-12-29 2016-08-10 北京科信必成医药科技发展有限公司 一种达非那新缓释制剂及其制备方法
CA2860553C (en) 2012-01-04 2016-08-23 Pfizer Limited N-aminosulfonyl benzamides
CA2861439C (en) 2012-02-03 2016-07-12 Pfizer Inc. Benzimidazole and imidazopyridine derivatives as sodium channel modulators
MD4590C1 (ro) 2012-03-06 2019-03-31 Pfizer Inc. Derivaţi macrociclici pentru tratamentul bolilor proliferative
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
WO2013152135A1 (en) 2012-04-04 2013-10-10 Dawei Zhang Substituted quinolines as bruton's tyrosine kinases inhibitors
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
EP2909212B1 (en) 2012-09-07 2017-02-22 Takeda Pharmaceutical Company Limited Substituted 1,4-dihydropyrazolo[4,3-b]indoles
CA2884921A1 (en) 2012-09-18 2014-03-27 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
US20150239842A1 (en) 2012-09-28 2015-08-27 Pfizer Inc. Benzamide and heterobenzamide compounds
JP2015531395A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
CA2885253A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
WO2014053965A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Tropomyosin-related kinase inhibitors
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
CA2890009C (en) 2012-11-08 2017-11-28 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
MD20150037A2 (ro) 2012-11-08 2015-11-30 Pfizer Inc. Compuşi heteroaromatici şi utilizarea lor ca liganzi de dopamină D1
CN104837836B (zh) 2012-11-21 2018-07-03 拉夸里亚创药株式会社 多晶型物
NZ707752A (en) 2012-12-03 2020-01-31 Pfizer Novel selective androgen receptor modulators
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
PL3431475T3 (pl) 2013-02-21 2021-09-13 Pfizer Inc. Stałe postacie selektywnego inhibitora CDK4/6
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
EA201591644A1 (ru) * 2013-03-13 2016-05-31 Ратиофарм Гмбх Лекарственная форма, содержащая кризотиниб
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
EP2997084A4 (en) 2013-05-17 2016-10-12 Acupac Packaging Inc WATER-FREE HYDROGELIC COMPOSITION
ES2948192T3 (es) 2013-06-27 2023-09-01 Pfizer Compuestos heteroaromáticos y su uso como ligandos de dopamina D1
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
WO2015092614A1 (en) 2013-12-20 2015-06-25 Pfizer Inc. Activating notch alterations in breast cancer
US20170305857A1 (en) 2013-12-20 2017-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
AR099052A1 (es) 2014-01-09 2016-06-29 Takeda Pharmaceuticals Co Derivados de azaindol
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
WO2015159175A1 (en) 2014-04-15 2015-10-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
MX2016013968A (es) 2014-04-25 2016-11-15 Pfizer Compuestos heteroaromaticos y su uso como ligandos de dopamina d1.
TN2016000447A1 (en) 2014-04-25 2018-04-04 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands.
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CA2946990A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heterocyclic compounds and their use as dopamine d1 ligands
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2015173684A1 (en) 2014-05-15 2015-11-19 Pfizer Inc. Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
ES2747989T3 (es) 2014-05-20 2020-03-12 Raqualia Pharma Inc Sal de derivado de benzisoxazol
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
JP2017516803A (ja) 2014-05-30 2017-06-22 ファイザー・インク ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド
EP3154979B1 (en) 2014-06-12 2018-03-07 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
MY185765A (en) 2014-06-17 2021-06-06 Pfizer Substituted dihydroisoquinolinone compounds
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
WO2016044433A2 (en) 2014-09-16 2016-03-24 Biopharma Works Metformin derivatives
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
WO2016097918A1 (en) 2014-12-18 2016-06-23 Pfizer Inc. Pyrimidine and triazine derivatives and their use as axl inhibitors
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
UY39011A (es) 2015-01-22 2021-02-26 Phytoplant Res S L Métodos para purificar cannabinoides, composiciones y kits de estos
CN107278205A (zh) 2015-02-24 2017-10-20 辉瑞大药厂 用作抗癌药的取代的核苷衍生物
US10624972B2 (en) 2015-03-13 2020-04-21 Endocyte, Inc. Conjugates for treating diseases
EP3286178A1 (en) 2015-04-21 2018-02-28 Almirall S.A. Amino-substituted heterocyclic derivatives as sodium channel inhibitors
PE20180395A1 (es) 2015-06-04 2018-02-28 Pfizer Formas de dosificacion solidas de palbociclib
BR112018000041A2 (pt) 2015-07-31 2018-09-04 Pfizer Inc. Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
WO2017098367A1 (en) 2015-12-10 2017-06-15 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
CN108473467B (zh) 2015-12-24 2021-08-13 武田药品工业株式会社 共结晶、其制造方法及含有共结晶的药物
CN109328059B (zh) 2016-01-07 2021-08-17 Cs制药技术有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
RU2712455C1 (ru) 2016-01-15 2020-01-29 Пфайзер Инк. 6,7,8,9-тетрагидро-5h-пиридо[2,3-d]азепиновые лиганды дофаминовых рецепторов d3
CN108697688A (zh) 2016-01-20 2018-10-23 塞拉维达公司 用于治疗多汗症的方法和组合物
US11753626B2 (en) 2016-03-09 2023-09-12 Beijing Percans Oncology Co., Ltd. Tumor cell suspension cultures and related methods
PL3436447T3 (pl) 2016-03-31 2021-12-27 Takeda Pharmaceutical Company Limited Kompleksy triazolonu izochinolinylowego
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
AU2017310526B2 (en) 2016-08-12 2021-08-12 Edwin J. Iwanowicz Protein kinase regulators
HRP20210871T1 (hr) 2016-08-15 2021-07-09 Pfizer Inc. Piridopirimdinonski inhibitori cdk2/4/6
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US11306075B2 (en) 2016-12-20 2022-04-19 Oligomerix, Inc. Benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
JP7273723B2 (ja) 2016-12-20 2023-05-15 オリゴメリックス インコーポレイテッド タウオリゴマーの形成を阻害する新規キナゾリノン及びその使用方法
CA3050625C (en) 2017-01-20 2021-07-20 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
WO2018134698A1 (en) 2017-01-23 2018-07-26 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
SG11201906414VA (en) 2017-01-24 2019-08-27 Pfizer Calicheamicin derivatives and antibody drug conjugates thereof
WO2018183145A1 (en) 2017-03-26 2018-10-04 Takeda Pharmaceutical Company Limited Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
EP3642198B1 (en) 2017-06-22 2022-03-16 Curadev Pharma Limited Small molecule modulators of human sting
KR102782200B1 (ko) 2017-08-30 2025-03-17 에이제이 사이언시즈 (이씽) 코., 엘티디 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드
WO2019051469A1 (en) 2017-09-11 2019-03-14 Krouzon Pharmaceuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
CA3082287C (en) 2017-11-14 2023-02-28 Pfizer Inc. Ezh2 inhibitor combination therapies
MX2020007960A (es) 2018-01-29 2020-09-24 Phytoplant Res S L Metodos para purificar cannabinoides usando cromatografia liquido-liquido.
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
EP3758753A1 (en) 2018-02-27 2021-01-06 Pfizer Inc Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
CU20200070A7 (es) 2018-04-26 2021-05-12 Pfizer Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de quinasa dependientes de ciclina
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
EP3823723A1 (en) 2018-07-19 2021-05-26 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
CA3127290A1 (en) 2019-01-23 2020-07-30 Pfizer Inc. Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
CU20210065A7 (es) 2019-01-31 2022-04-07 Pfizer Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
EP3930714A4 (en) 2019-02-27 2022-10-26 Madera Therapeutics, LLC USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS
AR118471A1 (es) 2019-03-22 2021-10-06 Takeda Pharmaceuticals Co Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
PH12021552760A1 (en) 2019-04-29 2022-08-15 Solent Therapeutics Llc 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
AU2020319160A1 (en) 2019-07-25 2022-01-27 Curadev Pharma Pvt. Ltd. Small molecule inhibitors of acetyl coenzyme A synthetase short chain 2 (ACSS2)
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
MX2022003177A (es) 2019-09-16 2022-04-06 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol.
WO2021161230A1 (en) 2020-02-12 2021-08-19 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
WO2021176349A1 (en) 2020-03-05 2021-09-10 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
US20230119013A1 (en) 2020-04-08 2023-04-20 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CA3181415A1 (en) 2020-05-01 2021-11-04 Pfizer Inc. Azalactam compounds as hpk1 inhibitors
BR112022022184A2 (pt) 2020-05-04 2023-01-17 Takeda Pharmaceuticals Co Derivados de n-(piperidin-4-il)benzamida agindo luminalmente
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
MX2022014429A (es) 2020-05-28 2022-12-07 Mission Therapeutics Ltd N-cianopirrolidinas con actividad como inhibidores de usp30.
AU2021285130A1 (en) 2020-06-04 2023-01-19 Mission Therapeutics Limited N-cyanopyrrolidines with activity as USP30 inhibitors
DK4161929T3 (da) 2020-06-08 2025-08-18 Mission Therapeutics Ltd 1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
US20230242539A1 (en) 2020-07-15 2023-08-03 Pfizer Inc. Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
US20240116937A1 (en) 2020-07-15 2024-04-11 Pfizer Inc. Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
US20230321042A1 (en) 2020-07-20 2023-10-12 Pfizer Inc. Combination therapy
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
JP2023537595A (ja) 2020-08-13 2023-09-04 ファイザー・インク 併用治療
MX2023003054A (es) 2020-09-15 2023-04-05 Pfizer Formas solidas de un inhibidor de cdk4.
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ｒｉｐｋ２抑制劑之３－（６－胺基吡啶－３－基）苯甲醯胺衍生物
WO2022077034A1 (en) 2020-10-09 2022-04-14 Napa Therapeutics Ltd. Heteroaryl amide inhibitors of cd38
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
WO2022137174A1 (en) 2020-12-22 2022-06-30 Pfizer Inc. Solid forms of an eif4e inhibitor
CA3206153A1 (en) 2020-12-24 2022-06-30 Pfizer Inc. Solid forms of a cdk2 inhibitor
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
JP2024510666A (ja) 2021-03-24 2024-03-08 ファイザー・インク Ｄｄｒ遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ
CA3213593A1 (en) 2021-03-31 2022-10-06 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
CN117545751A (zh) 2021-04-07 2024-02-09 生命爱科 作为ulk1/2抑制剂的2,4-二氨基嘧啶衍生物及其用途
WO2022229846A1 (en) 2021-04-29 2022-11-03 Pfizer Inc. Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
CR20230604A (es) 2021-06-26 2024-02-19 Array Biopharma Inc Inhibidores de mutación de her2
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy
CN118019738A (zh) 2021-08-11 2024-05-10 库拉德夫制药私人有限公司 作为sting拮抗剂的小分子脲衍生物
CA3228528A1 (en) 2021-08-11 2023-02-16 Monali BANERJEE Small molecule sting antagonists
WO2023084459A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating sars-cov-2
JP2024544660A (ja) 2021-12-01 2024-12-03 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン
MX2024006741A (es) 2021-12-01 2024-06-19 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Compuestos.
AU2022402512A1 (en) 2021-12-02 2024-06-20 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
US20250188037A1 (en) 2022-03-30 2025-06-12 Takeda Pharmaceutical Company Limited N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
EP4554674A1 (en) 2022-07-15 2025-05-21 Jazz Pharmaceuticals Ireland Limited Biaryl ether urea compounds as faah inhibitors
AU2023316863A1 (en) 2022-07-29 2025-02-13 Pfizer Inc. Novel acc inhibitors
TW202417456A (zh) 2022-08-10 2024-05-01 日商武田藥品工業股份有限公司 雜環化合物
WO2024033513A1 (en) 2022-08-11 2024-02-15 Diaccurate Compounds for treating cancer
EP4598538A1 (en) 2022-10-05 2025-08-13 Sevenless Therapeutics Limited New treatments for pain
TW202434599A (zh) 2022-11-15 2024-09-01 英商克拉德夫製藥有限公司 造血前驅細胞激酶1之吡啶酮及嘧啶酮抑制劑
IL321429A (en) 2023-01-13 2025-08-01 Neurim Pharmaceuticals 1991 Ltd Piromelatine for treating parasomnias associated with loss of rem sleep atonia
WO2024157205A1 (en) 2023-01-26 2024-08-02 Takeda Pharmaceutical Company Limited 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
WO2024214046A1 (en) 2023-04-14 2024-10-17 Takeda Pharmaceutical Company Limited Pyrazolopyrimidine derivatives as inhibitors of nlrp3
WO2024251978A1 (en) 2023-06-09 2024-12-12 Institut Gustave Roussy Drug conjugate targeting ctla4, products comprising the same and therapeutic uses thereof
TW202500155A (zh) 2023-06-12 2025-01-01 美商亞文納營運公司 雌激素受體降解劑之固體口服劑型
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
TW202513071A (zh) 2023-08-14 2025-04-01 以色列商琉璃藥品 (1991) 有限公司 Gal475組合物及其使用方法
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
WO2025074305A1 (en) 2023-10-04 2025-04-10 Takeda Pharmaceutical Company Limited N-(1-(aminomethyl)cyclopropyl)(aryl or heteroaryl) carboxamide derivatives
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
GB202319181D0 (en) 2023-12-14 2024-01-31 Imperial College Innovations Ltd Nora Inhibitors
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025168601A1 (en) 2024-02-05 2025-08-14 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases
WO2025231370A1 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited Inhibitors of cd38
WO2025229624A2 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited New cd38 inhibitors
WO2025233837A1 (en) 2024-05-07 2025-11-13 Takeda Pharmaceutical Company Limited 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
PT93637A (pt) * 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness

Also Published As

Publication number Publication date
ZA967745B (en) 1998-03-13
TW442300B (en) 2001-06-23
ATE233090T1 (de) 2003-03-15
CZ73298A3 (cs) 1999-03-17
JPH10511112A (ja) 1998-10-27
PT1245231E (pt) 2004-10-29
DE69632753D1 (de) 2004-07-22
NZ316924A (en) 1999-06-29
NO2005009I1 (no) 2005-04-18
US6106864A (en) 2000-08-22
MX9802026A (es) 1998-08-30
EP1245231A2 (en) 2002-10-02
HU225236B1 (en) 2006-08-28
CA2230314C (en) 2003-06-24
WO1997009980A1 (en) 1997-03-20
CY2468B1 (en) 2005-06-03
TR199800461T1 (xx) 1998-05-21
EP0850059A1 (en) 1998-07-01
EP1245231B1 (en) 2004-06-16
HU227397B1 (en) 2011-05-30
MY125662A (en) 2006-08-30
KR19990044653A (ko) 1999-06-25
EG23826A (en) 2007-09-25
CY2005007I2 (el) 2009-11-04
RU2163803C2 (ru) 2001-03-10
ES2224002T3 (es) 2005-03-01
AU6927596A (en) 1997-04-01
DE69626397D1 (de) 2003-04-03
ATE269076T1 (de) 2004-07-15
DE122005000024I2 (de) 2006-11-23
CA2230314A1 (en) 1997-03-20
LU91163I2 (fr) 2005-06-20
BR122012014331A2 (cs) 1999-01-05
KR100348585B1 (ko) 2002-10-31
BR122012014331A8 (pt) 2018-07-31
CO4750822A1 (es) 1999-03-31
BR9610153A (pt) 1999-01-05
IL122746A (en) 2000-12-06
HUP9802339A2 (hu) 1999-08-30
ES2188782T3 (es) 2003-07-01
DE122005000024I1 (de) 2005-08-04
CZ294024B6 (cs) 2004-09-15
BR122012014331B8 (pt) 2021-05-25
DE69632753T2 (de) 2005-07-14
NO981073D0 (no) 1998-03-11
DK1245231T3 (da) 2004-10-25
EP1245231A3 (en) 2003-01-15
NL300190I2 (nl) 2005-08-01
CN1195984A (zh) 1998-10-14
HUP9802339A3 (en) 1999-09-28
NL300190I1 (nl) 2005-07-01
CN1303998C (zh) 2007-03-14
AU703866B2 (en) 1999-04-01
FR05C0019I1 (cs) 2005-05-27
NO2005009I2 (no) 2006-11-27
DE69626397T2 (de) 2003-07-17
AR005231A1 (es) 1999-04-28
PL325598A1 (en) 1998-08-03
DK0850059T3 (da) 2003-03-31
CY2005007I1 (el) 2009-11-04
BR122012014331B1 (pt) 2019-10-08
CY2585B2 (en) 2009-11-04
GB9518953D0 (en) 1995-11-15
JP3403203B2 (ja) 2003-05-06
PL185604B1 (pl) 2003-06-30
IL122746A0 (en) 1998-08-16
NO981073L (no) 1998-03-11
FR05C0019I2 (cs) 2005-11-04
EP0850059B1 (en) 2003-02-26
HU0500976D0 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
NO314783B1 (no) Farmasoytiske formuleringer inneholdende darifenacin
AU2004268663B2 (en) Sustained release dosage forms of ziprasidone
KR20040037026A (ko) 심장병 및 순환성 질병을 치료하고 예방하기 위한 하루1회 요법용 제어방출형 경구 약제학적 조성물
WO2011039686A1 (en) Latrepirdine oral sustained release dosage forms
US20160243002A1 (en) Multilayer minitablets with different release rates
US20040146556A1 (en) Oral extended release tablets and methods of making and using the same
WO2003017983A1 (en) A new extended release oral dosage form
AU703866C (en) Pharmaceutical formulations containing darifenacin
AU726814B2 (en) Pharmaceutical formulations containing darifenacin
MXPA98002026A (en) Pharmaceutical formulations containing darifenac
WO2003017984A1 (en) A new extended release oral dosage form
AU2002327992A1 (en) a new extended release oral dosage form

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: EMSELEX (7,5 MG DEPOTTABLETT MED 7,14,28,49,56 OG 98 TABLETTER I BLISTERPAKNING OG 15 MG DEPOTTABLETT MED 7,14,28,49,56 OG 98 TABLETTER I BLISTERPAKNING); NAT. REG.NO/DATE: NO , 04/294/1-12 20041022

Spc suppl protection certif: 2005009

Filing date: 20050408

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: EMSELEX (7,5 MG DEPOTTABLETT MED 7,14,28,49,56 OG 98 TABLETTER I BLISTERPAKNING OG 15 MG DEPOTTABLETT MED 7,14,28,49,56 OG 98 TABLETTER I BLISTERPAKNING); NAT. REG.NO/DATE: NO , 04/294/1-12 20041022

Spc suppl protection certif: 2005009

Filing date: 20050408

Extension date: 20191022

Effective date: 20061120

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERUS LABS NETHERLANDS BV, NL

MK1K Patent expired
SPCX Expiry of an spc

Free format text: PRODUCT NAME: EMSELEX-DARIFENACIN. IUPAC-NAVN: (S)-2-{1-¢2-(2,3-DIHYDROBENZOFURAN-5-YL)ETYL!-3-PYRROLIDINYL}-2,2-DIFENYLACETAMID

Spc suppl protection certif: 2005009